Despite a biotech funding environment marked by declines and uncertainty, several companies have successfully raised capital to fuel innovation. Frazier Life Sciences secured $1.3 billion in its latest venture fund focusing on early-stage biopharmaceuticals, Strand Therapeutics raised $153 million to advance programmable mRNA cancer therapies, and Positive Development garnered $51.5 million to expand its developmental therapy model for autism. However, some firms, including Dewpoint Therapeutics and Iovance Biotherapeutics, have downsized staffs in response to commercial and pipeline challenges.